Evidence map›Paper›PMID 30619775›Full record

ArticleFrontiers in cellular and infection microbiology2018

Serum Levels of Soluble CD40 Ligand and Neopterin in HIV Coinfected Asymptomatic and Symptomatic Visceral Leishmaniasis Patients.

Wim Adriaensen, Saïd Abdellati, Saskia van Henten, Yonas Gedamu, Ermias Diro, Florian Vogt, Bewketu Mengesha, Emebet Adem, Luc Kestens, Johan van Griensven

Open access · goldAbstract read
In one paragraph

Article in Frontiers in cellular and infection microbiology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.7field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 12 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 2 countries.

Wim AdriaensenUnit of NTDs, Department of Clinical Sciences, Institute of Tropical Medicine, Antwerp, Belgium.
Saïd AbdellatiUnit of NTDs, Department of Clinical Sciences, Institute of Tropical Medicine, Antwerp, Belgium.
Saskia van HentenUnit of NTDs, Department of Clinical Sciences, Institute of Tropical Medicine, Antwerp, Belgium.
Yonas GedamuDepartment of Internal Medicine, Leishmaniasis Research and Treatment Centre, University of Gondar, Gondar, Ethiopia.
Ermias DiroDepartment of Internal Medicine, Leishmaniasis Research and Treatment Centre, University of Gondar, Gondar, Ethiopia.
Florian VogtUnit of NTDs, Department of Clinical Sciences, Institute of Tropical Medicine, Antwerp, Belgium.
Bewketu MengeshaDepartment of Internal Medicine, Leishmaniasis Research and Treatment Centre, University of Gondar, Gondar, Ethiopia.
Emebet AdemDepartment of Internal Medicine, Leishmaniasis Research and Treatment Centre, University of Gondar, Gondar, Ethiopia.
Luc KestensUnit of Immunology, Department of Biomedical Sciences, Institute of Tropical Medicine, Antwerp, Belgium.
Johan van GriensvenUnit of NTDs, Department of Clinical Sciences, Institute of Tropical Medicine, Antwerp, Belgium.
Instituut voor Tropische Geneeskunde · BEUniversity of Gondar · ET

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Human Immunodeficiency Virus (HIV) co-infection drastically increases the risk of developing overt visceral leishmaniasis (VL). The asymptomatic

Indexed as

CoinfectionAdolescentAdultAsymptomatic InfectionsBiomarkersCD40 LigandCohort StudiesFemaleHIV InfectionsHumansLeishmania donovaniLeishmaniasis, VisceralMaleMiddle AgedNeopterinYoung AdultBiomarkersCD40 LigandNeopterinasymptomaticHIVkala-azarneopterinsCD40Lvisceral leishmaniasis

Identifiers

PMID30619775
PMCPMC6297181
OpenAlexW2904702185

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.